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Introduction
As the HIV epidemic approaches its fourth decade, effective 
prevention remains elusive in the communities most affected by the 
virus. An estimated 36.9 million people were living with HIV globally by 
end 2014 [1] of whom 70% in sub-Saharan Africa. In 2014, an estimated 
1.4 million people acquired HIV infection; 66% of these new infections 
and 66% of all HIV-related deaths occurred in sub-Saharan Africa, 
a region disproportionately affected by the epidemic. Remarkable 
strides have been made recently towards combating the epidemic and 
increasing antiretroviral therapy (ART) coverage with considerable 
reduction in mortality and morbidity [2], such that in 2014, 40% of all 
people living with HIV were receiving ART. Following the results of the 
START [3] and TEMPRANO [4] trials, the World Health Organisation 
(WHO) now recommends ART regardless of CD4 count [5], a policy 
that would maximise both the individual and population health benefit 
of ART. This aligns with the recent UNAIDS target of 90:90:90 (90% 
of people living with HIV aware of their HIV status, 90% of people 
diagnosed HIV-positive on ART, 90% of people on ART virologically 
suppressed) in 2020 [6], but will require huge financial investments and 
commitments from governments to bear fruit.
It is now well-recognised that prevention approaches need to be 
combined to accelerate the effective prevention of HIV acquisition and 
transmissions [7]; HIV programme planning have now moved from the 
implementation of single preventive methods to combination context-
specific prevention approaches, for which evidence of effectiveness 
exists. 
This paper reviews currently available HIV prevention methods, 
highlighting the strengths and weaknesses of past prevention 
approaches, draws attention to the present array of prevention 
armamentarium available and conceptualises how these could be 
combined towards the goal of HIV elimination.
Abstract
Introduction: Remarkable strides have been made in controlling the HIV epidemic, although not enough to 
achieve epidemic control. More recently, interest in biomedical HIV control approaches has increased, but substantial 
challenges with the HIV cascade of care hinder successful implementation. We summarise all available HIV prevention 
methods and make recommendations on how to address current challenges.
Discussion: In the early days of the epidemic, behavioural approaches to control the HIV dominated, and the few 
available evidence-based interventions demonstrated to reduce HIV transmission were applied independently from 
one another. More recently, it has become clear that combination prevention strategies targeted to high transmission 
geographies and people at most risk of infections are required to achieve epidemic control. Biomedical strategies 
such as male medical circumcision and antiretroviral therapy for treatment in HIV-positive individuals and as pre-
exposure prophylaxis in HIV-negative individuals provide immense promise for the future of HIV control. In resource-
rich settings, the threat of HIV treatment optimism resulting in increased sexual risk taking has been observed and 
there are concerns that as ART roll-out matures in resource-poor settings and the benefits of ART become clearly 
visible, behavioural disinhibition may also become a challenge in those settings. Unfortunately, an efficacious vaccine, 
a strategy which could potentially halt the HIV epidemic, remains elusive. 
Conclusion: Combination HIV prevention offers a logical approach to HIV control, although what and how the 
available options should be combined is contextual. Therefore, knowledge of the local or national drivers of HIV 
infection is paramount. Problems with the HIV care continuum remain of concern, hindering progress towards the 
UNAIDS target of 90-90-90 by 2020. Research is needed on combination interventions that address all the steps of 
the cascade as the steps are not independent of each other. Until these issues are addressed, HIV elimination may 
remain an unattainable goal.
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HIV Prevention
Behavioural prevention 
Behavioural prevention approaches include: delaying onset of 
first intercourse, decreasing the number of sexual partners, increasing 
the number of sexual acts protected, counselling and testing for HIV 
including repeat HIV testing, encouraging adherence to biomedical 
HIV prevention strategies, decreasing sharing of needles and syringes 
and reducing substance use [8].
A 2010 review of behavioural intervention trials, with HIV incidence 
as main outcome, showed no significant reduction in HIV incidence 
in any of the nine randomised-controlled trials studied [9]. Project 
Accept (HPTN 043), is a cluster-randomised trial evaluating whether 
a multicomponent social and behavioural prevention approach could 
reduce HIV incidence. In this trial community-based versus facility-
based HIV counselling and testing showed no significant reduction 
in HIV incidence overall (relative risk [RR] 0·86, 95% CI 0·73–1·02) 
although there was a significant reduction in HIV incidence in he sub-
group of women > 24 years of age (RR=0·70, 0·54–0·90) [10].
Structural interventions 
HIV-associated structural factors are defined as the physical, 
social, cultural, organizational, community, economic, legal or policy 
aspects of the environment that impede or facilitate persons’ efforts to 
avoid HIV infection [11] For example, laws that discriminate against 
certain HIV risk groups such as men who have sex with men (MSM) 
or injecting drug users may stigmatise and hinder access to HIV 
prevention services. Similarly, cultural norms which perpetuate gender 
inequity may leave women economically dependent on men and unable 
to negotiate condom use for fear of abandonment [12]. Interventions 
addressing these factors tend to be complex and context-specific; 
they do not seek to address risky behaviours directly, but address the 
prevailing circumstances which give rise to risky behaviours, acting 
on factors distal to the HIV outcome of interest. Distal factors may 
impact the outcome through multiple causal pathways making them 
difficult to evaluate; replication in other environments is challenging. 
One of the structural interventions receiving attention recently is the 
use of social cash transfers to encourage safer sex and a reduction in 
HIV acquisition. A randomised control trial in Lesotho using a lottery 
scheme as an incentive to reduce risky sexual behaviour showed a 
25% (OR 0.75, 95% CI 0.58 – 0.97) reduction in HIV incidence over 
2 years [13]. A cluster randomised trial (CRT) in Malawi showed that 
cash incentives to young women and their households reduced HIV 
prevalence by 64% at 18 months; but making the payments conditional 
on school attendance made no difference to the reduction in HIV 
infection observed [14]. However a recently concluded CRT in South 
Africa showed that a conditional cash transfer to young women 
and men tied to HIV testing, participation in life skills training and 
academic attainment reduced the incidence of HSV-2 by 30% but did 
not have an impact on HIV incidence after 24 months [15]. Similarly, 
another recently concluded randomised trial in South Africa found that 
cash transfer which is conditional on 80% school attendance by young 
women showed no reduction in HIV incidence after 3 years [16]. These 
results suggest that the effectiveness of social cash transfer could be 
context specific.
Treatment of sexually transmitted infections (STIs)
Substantial evidence exists from observational studies suggesting 
an increased risk of HIV acquisition with both curable STIs and 
genital herpes [17,18]. STIs have also been associated with increased 
HIV infectiousness, although this has not been quantified directly in 
observational studies [19]. HIV-STI co-infection appears more likely 
to result in HIV transmission than infection with HIV alone [20,21]
However, nine randomised trials to date (four cluster randomised 
trials, two individual randomised trials on treating curable STIs and 
three individual randomised trials on Herpes suppressive therapy) 
have together failed to confirm the hypothesis that STI treatment 
would reduce HIV transmission and acquisition [19]. Of the four 
cluster-randomised trials examining the impact of STI treatment on 
HIV incidence, only the Mwanza trial in Tanzania showed syndromic 
treatment of STIs to be associated with a 40% significant reduction 
in HIV incidence [22]. Various factors may explain the differences in 
effect between trials, including differences in the HIV epidemic phase, 
enhanced interventions in the control group, and higher prevalence of 
STIs in the Mwanza trial compared to the other sites [19]. 
Syndromic treatment of STIs focusses on patients presenting with 
symptoms, but provision of inadequate treatment and poor adherence 
could result in low effectiveness of syndromic treatment, which was 
estimated to be only 13% for curable STIs in rural KwaZulu-Natal [23]. 
Further, a significant proportion of STIs are asymptomatic [24] and 
the large pool of untreated individuals with asymptomatic STIs will 
continue to transmit HIV. This situation coupled with poor uptake of 
partner notification could result in significant rates of STI reinfections 
and will likely impact HIV transmission and acquisition.
The effect of herpes simplex virus (HSV) suppressive therapy on 
HIV incidence has been evaluated in two randomised trials; the first 
one in high-risk HSV-2 positive, HIV negative women in Tanzania [25] 
and the second involving women from three sites in Africa (Harare, 
Lusaka, Johannesburg) and MSM from Peru and the USA [26]. In these 
trials, treating HIV negative, HSV-2 positive individuals with aciclovir 
did not result in decreased HIV acquisition. A third randomised trial 
investigated the impact of HSV-2 suppressive therapy in HIV positive 
individuals on the risk of HIV transmission. Although suppressive 
therapy with acyclovir reduced HIV plasma viral load by about 0.25 
log10 and genital ulcers due to HSV-2 by 73%, there was no significant 
effect on HIV transmission (RR 0.92, 95% CI 0.60-1.41).
Although, these results are disappointing there remains compelling 
biological and epidemiological evidence that STIs are co-factors for 
HIV acquisition and transmission [27] and treatment of STIs should be 
part of the HIV care and prevention programme. 
Male circumcision
A meta-analysis of 27 published observational studies on male 
circumcision in sub-Saharan Africa [28] provided evidence that male 
circumcision protects against HIV acquisition. 
Male circumcision was shown to be protective against HIV 
acquisition in three randomised controlled trials in South Africa, 
Uganda and Kenya [29-31]; in pooled analysis the combined incidence 
risk ratio (IRR) at 12 months was 0.50 (95% CI 0.34-0.72) and 0.46 
(95% CI 0.34-0.62) at 21 or 24 months [32].
These observations in heterosexual HIV acquisition raised the 
question of whether this protection would also be observed in MSM. 
However, an observational analysis of data from a randomised controlled 
trial of HSV-2 suppressive therapy to prevent HIV acquisition found no 
evidence that circumcision was associated with reduced HIV incidence 
in MSM who practised predominantly insertive sex (RR 0.31, 95% CI: 
0.06-1.51) [33]
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vaginal tenofovir gel). More adverse events due to genital lesions were 
reported in the nonoxynol-9 trials while these events were similar in both 
the microbicide and placebo arms of the other trials.
Antiretroviral treatment 
The efficacy of antiretroviral therapy at preventing HIV transmission 
has been demonstrated in a variety of clinical scenarios such as in the 
prevention of mother-to-child [36,37], and heterosexual transmission [38], 
which led to the declaration that an HIV infected individual who is on 
ART and has undetectable viral loads for at least 6 months with no STIs is 
sexually non-infectious [39]. Other uses include post-exposure prophylaxis 
in HIV-negative individuals after occupational or sexual exposure to body 
fluids from known or suspected HIV-positive individuals [40-43].
Oral and topical ART-based pre-exposure prophylaxis: More 
recently, studies have shown that ART could also be used by HIV-
negative individuals prior to exposure to HIV to prevent HIV 
acquisition, known as pre-exposure prophylaxis (PrEP).
Table 1 summarises the 11 trials on pre-exposure prophylaxis using 
Non-ART vaginal microbicides
Initial research involving microbicides focused on non-ART related 
compounds, with a recent shift to ART-related compounds following 
multiple failures of the former to demonstrate effectiveness in the 
prevention of HIV acquisition in women. 
These earlier compounds were surfactants (nonoxynol-9) which 
disrupt the cell membranes of bacteria and viruses, polyanions (Carraguard, 
cellulose sulphate and PRO 2000) which interfere with the attachment of 
the virus to target cells in the mucosa and vaginal milieu, and protectors 
(BufferGel) which render the vagina acidic. In an acidic environment, 
sperms and viruses are inactivated or killed [34]. A recent meta-analysis 
of 13 randomised controlled trials involving 35,905 HIV negative women 
from Africa, India, Thailand and the United States of America between 
1996 -2011 showed no protective effects on HIV acquisition (RR 0.97, 
95% CI: 0.87-1.08) [35]. This meta-analysis included mostly non-ART 
related microbicides; five trials of nonoxynol-9, two trials of SAVVY, 
two of cellulose sulphate, one of Carraguard, one of PRO 2000 and one 
of BufferGel and one ART-related microbicide (CAPRISA 004 with 1% 
Author Study setting Sample size 
contributing 
data
Study Population Intervention/Control Follow-up 
time/Person 
years
HIV seroconversions Impact on HIV 
incidence (95% CI)
Peterson, L 
2007[44]
Ghana, 
Cameroun, 
Nigeria
936 18-35 year old high risk 
HIV negative women
Intervention: Oral daily 
tenofovir (TDF) Control: 
Placebo
476 Intervention: 2
Control: 6
Rate ratio (RR) 0.35 
(0.03-1.93) 
Abdool Karim, Q 
2010[45] (CAPRISA 
004)
South Africa 889 18-40 year old HIV-
negative women
Intervention: coitally 
administered 1% vaginal 
gel formulation of TDF
Control: Placebo
1341 Intervention:38
Control:60
RR 0.61(0.40-0.94)
Grant RM, 2010[51] 
(iPrEX study)
Peru, Ecuador, 
South Africa, 
Brazil, 
Thailand, USA 
2499 >18 years, HIV negative 
MSM or transgender
Intervention: Oral daily 
tenofovir/emtricitabine 
(TDF-FTC)
Control: Placebo
3324 Intervention: 36
Control: 64
44% reduction 
(15-63)
Thigpen MC, 
2012[52] (TDF2 
Study)
Botswana 1219 18-39 years, HIV negative 
men and women
Intervention: Oral daily 
TDF-FTC
Control: Placebo
1563 Intervention:9
Control:24
62.2% reduction 
(21.5-83.4)
Baeten J.M, 
2012[53] Partners 
PrEP Study
Kenya, Uganda 4747 Heterosexual HIV 
serodiscordant couples 
Interventions: i) Once daily 
oral TDF ii) Once daily 
TDF-FTC
Control: Placebo
7830 Interventions: TDF 17 
TDF/FTC: 13
Control: 52
67% reduction due 
to TDF (44-81)
75% reduction due 
to TDF/FTC (55-87)
Van Damme L, 
2012[46] FEM-
PrEP Study
Kenya, 
South Africa, 
Tanzania
2056 18-35 years, HIV negative 
women
Intervention: Oral daily 
TDF-FTC
Control: Placebo
1407 Interventions: 33
Control: 35
Hazard ratio (HR) 
0.94 (0.59-1.52)
Marrazzo J, 
2013[54] VOICE 
Study
South Africa, 
Zimbabwe, 
Uganda
5029 Mean age 25.3 years, HIV 
negative women
Intervention: i) Oral daily 
TDF ii)Oral daily TDF/FTC 
iii) 1% TDF vaginal gel
Control: i) Oral placebo ii) 
Placebo vaginal gel
5509 Interventions: i) oral 
TDF 52 ii) oral TDF-
FTC 61 iii) Vaginal TDF 
gel: 61
Control i) Placebo for 
oral TDF: 35
ii) Placebo for oral TDF/
FTC: 60 iii) Placebo for 
vaginal gel: 70
HR for Oral TDF 
1.49 (0.97-2.3)
HR for oral TDF/
FTC 1.04 (0.7-1.5)
HR for vaginal TDF 
gel 0.85 (0.6-1.2)
Choopanya K, 
2013 [55] Bangkok 
Tenofovir study
Bangkok, 
Thailand
2413 20-60 years, HIV negative 
and reported injecting drug 
use within the past year
Intervention: Oral tenofovir
Control: Placebo
9665 Intervention: 17
Placebo: 33
Efficacy of tenofovir 
48.9% (9.6-72.2)
Rees H, 2015 
FACTS 001
South Africa 2029 HIV negative women, 18-
30 years
Intervention: Pericoital 1% 
vaginal gel formulation of 
Tenofovir
Control: Placebo
3036 Intervention: 61
Control: 62
IRR 1.0 (0.7-1.4)
McCormack S, 
2015 PROUD
England 544 HIV negative MSM, ≥18 
years
Immediate: oral daily TDF/
FTC
Deferred: Oral daily TDF/
FTC after 12 months
465 Immediate: 3
Deferred: 20
86% reduction 
(64-96) 
Molina J-M, 2015 
IPERGAY
France, 
Canada
400 HIV negative adult MSM Intervention: On demand 
TDF/FTC
Control: Placebo
Intervention: 2
Control: 14
86% reduction 
(39.4-98.5)
Table 1: Oral and ART-based topical pre-exposure prophylaxis.
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ART completed to date. The first trial evaluating the effectiveness of 
once daily oral tenofovir for pre-exposure prophylaxis was conducted 
in three sites in Ghana, Cameroun and Nigeria among high risk HIV-
negative women aged 18-35 years [44]. The Nigeria and Cameroun 
sites were closed prematurely for unspecified reasons and as a result 
this trial lacked statistical power because of the small number of HIV 
seroconversions observed. In the CAPRISA 004, a proof-of-concept 
phase II trial including 889 HIV negative women, 1% tenofovir 
gel compared to placebo was shown to significantly decrease HIV 
acquisition, (RR 0.63, 95% CI 0.43-0.93) [45]. However, the results of 
three other PrEP trials, FEM-PrEP [46] , VOICE [47] and FACTS 001 
[48] conducted in women have been very disappointing with none of 
them demonstrating any efficacy. Substudies of adherence within these 
large trials showed that there was poor adherence to the study drug 
which could explain the lack of efficacy observed.
The placebo arm of two other PreP trials – IPERGAY [49] and 
PROUD [50] - were terminated early because of marked reduction in 
HIV acquisition in the intervention arm compared to the placebo arm
ART in HIV-discordant partnerships: Table 2 summarises 
the nine observational studies and one randomised-controlled trial 
evaluating the effectiveness of ART in preventing HIV transmission 
from the index to the HIV-uninfected partner. A Cochrane review and 
meta-analysis [56] of these observational studies identified 2112 HIV 
transmissions: 1,016 among ART-treated couple and 1096 in those not 
taking ART. The combined rate ratio for the nine observational studies 
was 0.58 (95% CI: 0.17-0.75). 
The one trial was a multicentre randomised-controlled trial (HPTN 
052) [38] involving 1763 stable serodiscordant couples from 9 countries 
(Table 2) which reported findings in 2011. HIV infected individuals 
with CD4 counts between 350-550 cells/µL and in a stable relationship 
with an uninfected partner were randomly allocated to receive ART 
immediately (early therapy) or delayed until CD4 count decreased 
below 250 cells/mm3 or development of clinical symptoms (deferred 
therapy). This study was stopped early because of clear efficacy of ART 
in preventing transmission in the early therapy arm. There were 39 
HIV transmissions in total of which 28 were virologically linked to 
the infected partner; of the linked transmissions, 27 occurred in the 
deferred and one in the early therapy group (HR 0.04, 95% CI: 0.01-
0.27). Besides the clear public health significance of this finding, there 
was also a clinical benefit to the individual if randomised to the early 
therapy arm. 
An earlier meta-analysis [57] reviewed observational studies of 
HIV transmission involving individuals on and not on ART from 
11 cohorts comprising 5021 heterosexual couples and 461 HIV 
Author Study setting No of 
couples
Study population Study design/
intervention
Follow-up 
duration in 
person years
ART status of 
index case &sero-
conversions (n)
Effect estimate
(95% CI)
Musicco, M 
1994[62]
Italy 436 Female sexual 
partners  of HIV-
infected males 
majority of whom were 
injecting drug users
Observational/
Zidovudine (ZDV) 
monotherapy
740 Partners of men not on 
ZDV:21
Partners of men on 
ZDV: 6
Risk lower in partners 
of treated Men
RR 0.50 (0.1-0.9)
Melo MG, 
2008[63]
Brazil 93 Female index case: 67
Male index case: 26
Observational/
41 on triple ART
52 not on ART
Not stated Partner on ART: 0
Partner not on ART : 6
Risk lower if partner 
on ART
RR 0.10 (0.01-1.67)
Sullivan P, 
2009[64]
Rwanda, Zambia 2993 HIV discordant 
couples
Observational 5609 Partner on ART: 4
Partner not on ART: 171
Risk lower if partner 
on ART
RR 0.21 (0.08-0.59)
Del Romero, J 
2010[65]
Spain 424 Stable sexual couples Observational
*144 couples with index 
partner on triple ART
*47 couples  on mono/dual 
ART
*341 couples with index 
partner not on ART
1355 Partner on ART: 0
Partner not on ART: 5
Risk lower if partner 
on ART
RR 0.21 (0.01-3.75)
Donnell D, 
2010[66]
Botswana, Kenya, 
Rwanda, South 
Africa, Tanzania, 
Uganda, Zambia
3381 HIV serodiscordant 
partners
Prospective cohort
349 initiated ART
3082 did not initiate ART
4831 Partner on ART: 1
Partner not on ART: 102
Risk lower if partner 
on ART
0.08 (0.00-0.57
Lu W, 2010[67] China 1927 HIV serodiscordant 
couples
Male index 1092
Female index 835
Prospective cohort
1369 on ART
558 not on ART
4918 Partner on ART:  66
Partner not on ART: 18
RR 1.44 (0.85-2.44)
Reynolds SJ,  
2011[68]
Uganda 250 HIV discordant 
couples
Male index: 145
Female index: 155
Prospective cohort
32 initiated ART
218 not on ART
513 Partner on ART: 0
Partner not on ART: 42
RR 0.10 (0.01-1.64)
Cohen MS, 
2011[38]
Botswana, Kenya, 
Malawi, South 
Africa, Zimbabwe, 
Brazil, India, 
Thailand, USA
1763 Stable HIV-discordant
97% heterosexual
Randomised controlled
Immediate versus deferred 
ART
3152 Early therapy: 1
Deferred therapy: 27
RR 0.04 (0.01-0.27)
Birungi J, 2012 
[69] 
Uganda 586    Serodiscordant 
couples
348 ART-eligible couples 
initiated 
238 not eligible for ART 
Median follow 
up of 1.3 years
ART group : 9
Non-ART group: 8
RR 0.91 (0.38-2.20)
Jia Z, 2012 [70] China 38, 862 Serodiscordant 
couples
24057 ART-treated
14,805 non-ART group
101,295 ART-group: 935
ART-naïve: 696 
RR 0.74 (0.65-0.84)
Table 2: ART for preventing HIV transmission in HIV discordant partnerships.
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transmission events. The HIV transmission risk in the five studies of 
individuals on ART, irrespective of viral load, was 0.46 (95% CI: 0.19-
1.09) based on five transmissions and 1098 person years of follow up. 
When this meta-analysis was restricted to the two studies in which 
individuals had undetectable viral load, no transmission was recorded 
in 291 person years of follow up with an upper confidence limit of 
1.27 per 100 person years.It is now established that ART is effective 
at preventing transmission in stable heterosexual couples, it remains 
unknown whether ART will be similarly effective at preventing HIV 
transmission at the population level. An observational study from rural 
KwaZulu-Natal suggests this to be the case [58]; and this question is 
currently being addressed by four randomised trials [59-61].
HIV vaccines
Recent HIV vaccine research has focused on antibody-based 
strategies following isolation of potent highly broadly neutralising 
monoclonal antibodies from infected individuals [71]. However, both 
arms of the adaptive immune system have important roles to play 
against HIV infection and or disease [71,72]. Neutralising antibody 
response aim to prevent acquisition of HIV infection, while cytotoxic 
T lymphocytes (CTL) response, which only recognises infected host 
cells, could play a role in controlling viral replication and disease 
progression. It is unclear if robust CTL response can eradicate HIV 
infection in humans [71].
Only one of the six HIV vaccine trials completed to date showed a 
protective efficacy (Table 3).
The VAX004 (North America and the Netherlands) and VAX003 
(Thailand) were protein subunit trials using rgp120 monomers as 
immunogens aiming to elicit neutralising antibodies. Both failed to 
show significant protection against HIV acquisition [73,74].
Another vaccine approach is based on recombinant viral vectors 
engineered to express the gene of interest. The recombinant adenovirus 
serotype 5 was used as the vector for the Step (North and South 
America, the Caribbean and Australia) and Phambili (South Africa) 
trials [75,76]. These trials assessed the ability of these vaccines to 
stimulate the cellular immune responses. The Step trial was terminated 
early on the grounds of futility and lack of control of early viraemia 
in those who became infected. Enrolment in the Phambili trial was 
stopped because of the results observed in the Step trial.
The HVTN 505 (USA), was a phase 11b DNA vaccine trial that 
evaluated a DNA prime expressing Gag, Pol, Nef and Env with a 
recombinant adenovirus serotype 5 boost expressing Gag, Pol and Env. 
This trial was also halted prematurely for futility [77].
The RV144 vaccine trial in Thailand employed a combination of 
vaccine approaches [78], comprising a canary pox viral vector prime 
expressing Env, Gag and Pol followed by a protein subunit vaccine 
boost (AIDSVAX B/E). The vaccine efficacy was 31% (95% CI, 1.1 
to 52.1) after 3.5 years. To date, this remains the only vaccine trial to 
demonstrate some protection against HIV acquisition.
Mathematical modelling 
Mathematical modelling has played a pivotal role in the 
understanding of HIV pathogenesis by elucidating virus kinetics in terms 
of virus production and clearance from blood and CD4 T-lymphocytes 
depletion [80,81]. This showed that HIV replicated at a very rapid rate 
and demonstrated the superiority of combination therapy over single 
drug therapy on virus kinetics. This early models also examined the 
role of long-lived and latently infected cell populations in the blood 
and the question as to whether combination therapy would be adequate 
to eradicate or cure HIV in an individual arose as a hypothesis. Later 
models have identified third and fourth phase decays in HIV kinetics 
through the use of single copy assays [82]. This discovery as opposed 
to the initial two-phase decay proposed in earlier models implies that 
combination therapy may not be sufficient to eliminate HIV within an 
individual. 
Models have also played significant roles in generating important 
hypothesis about the impact of immediate ART on HIV elimination 
from the general population. The model by Granich et al. [83] generated 
a lot of interest in this regard. This model predicted that yearly HIV 
testing followed by immediate ART coupled with male circumcision, 
behaviour change programmes, condoms and treatment of STIs could 
reduce HIV incidence to less than one case per 1000 per year within 10 
years and reduce the prevalence of HIV to less than 1% within 50 years. 
However the assumptions used to parameterise the model may be overly 
optimistic as the impact of such approaches have been shown by more 
recent models to be sensitive to factors such as uptake of HIV testing, 
linkage to care and ART coverage and the nature of the sexual networks 
[84-86]. There are challenges in achieving the sort of coverage required 
as illustrated by the leaks in the HIV care cascade described below. 
Mathematical models, in combination with empirical research 
would play pivotal role in understanding interventions and their 
expected impact on HIV prevention and elimination.
Barriers to HIV Elimination
HIV care cascade
For ART to succeed as an effective HIV prevention method, there 
Author Vaccine trial
(randomised-placebo 
controlled
Vaccine type Sample size Population Phase Intended immune 
response
Results
Flynn et al; 2005 [73] VAX004 Protein: rgp120 5400 Mostly high-risk MSM III Antibodies,
CD4+ T cells
6% (-17 to 24)
Pitisuttithum et al; 
2006 [74]
VAX003 Protein: rgp120 2500 Injection drug users III Antibodies, CD4+ 
T cells
0.1% ( -30.8 to 23.8)
Rerks-Ngarm et al; 
2009 [78]
RV144 Pox/protein: ALVAC/
grp120
16,403 Low risk heterosexuals III Antibodies, CD4+ & 
CD8 T cells
31% (1.1-52.1)  
Buchbinder, SP et al; 
2008 [75]
HVTN 502/Merck 023 
(STEP)
Adenovirus type 5 (Ad5) 
gag/pol/nef
3000 High risk MSM, 
heterosexual men and 
women
IIb CD8+ & CD4+ T 
cells
HR 1.2 (0.6-2.2)
Gray et al; 2011b [76] HVTN 503 (Phambili) Ad5 gag/pol/nef 801; original 
target  of 3000
Heterosexual men and 
women
IIb CD8+ & CD4+ T 
cells
HR 1·25 (0·76-2·05)
Hammer, S 2013 [79] HVTN 505 DNA-Ad5  gag/pol/
nef/env
2504 High risk MSM IIb Antibodies, CD4+ & 
CD8+ T cells
-25% (-121.2 to 29.3)
Table 3: Summary of HIV vaccine trials and outcomes.
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needs to be good coverage in all the steps of the HIV care pathway. 
The entry point into this pathway is HIV testing. Those testing HIV- 
positive need to be willing to initiate ART even when not clinically 
indicated for their own health, retained in care and be adherent lifelong. 
Equally important are those who tested negative. They should be aware 
of methods to protect themselves from HIV acquisition and be willing 
to test for HIV repeatedly for those who become HIV-positive to be 
linked to the care pathway.
HIV testing and linkage to care
HIV testing is necessary for linkage to HIV care and treatment. 
For HIV elimination, large numbers of individuals have to be willing 
to test for HIV regularly and those testing positive need to be linked to 
care and started on ART. However, despite the availability of effective 
treatment for HIV, 36% of individuals in SSA have never been tested for 
HIV [2], with low perception of risk, concerns about confidentiality and 
fear of disclosure, stigma and discrimination suggested as explanations. 
Gender inequity that leaves women economically dependent on men 
may undermine the ability of women to seek HIV testing [87-89].
Further, studies have shown a huge drop between the numbers of 
people taking an HIV test and linked to care. A systematic review and 
meta-analysis of eleven studies in SSA estimated that only 57% (95% CI, 
48-66) of those diagnosed HIV positive are linked to care [90]. Another 
meta-analysis of studies in the USA estimated that 69% (95% CI, 66-71) 
of individuals diagnosed with HIV entered into care averaged over the 
time intervals from 1995 to 2009 [91]. Substantially higher numbers 
of individuals need to be linked to care for treatment assessment to 
realise the goal of HIV elimination. In a review of studies examining 
the barriers to linkage, the most commonly identified factors include 
transport costs and distance to clinics. Others include concerns about 
disclosure and stigma, staff shortages, long clinic waiting times, male 
sex and younger age [92].
Adherence/Retention in Care
The WHO defines adherence as “the extent to which a person’s 
behaviour-taking medication, following a diet, and/or executing lifestyle 
changes, corresponds with agreed recommendations from a health care 
provider” [93]. Adherence to ART is vital for viral suppression [94], 
which is important for optimal treatment outcomes and for prevention 
of HIV transmission [95]. Studies reporting on routine treatment 
programmes with differing ART initiation CD4 thresholds have shown 
that individuals starting treatment at higher CD4 counts are less likely 
to adhere consistently than individuals starting at lower CD4 counts 
[96,97]. However in the HPTN 052 on stable sero-discordant couples, 
adherence measured by pill count of at least 95% was seen in 79% of 
participants in early therapy group (CD4 350-550 cells/mm3) compared 
to 74% in the delayed therapy group (CD4<250 cells/mm3) [38]. This 
may not be reflective of real life situations. It remains to be seen how 
evidence from the START [3] and TEMPRANO [4] trials which suggest 
individual benefit to early ART would influence adherence.
In the pre-exposure prophylaxis studies in which participants 
were aware that they were using the prescribed medications to prevent 
HIV transmission, adherence measured by drug levels was poor 
[46,54]. A meta-analysis involving 37 qualitative and 47 quantitative 
studies on barriers and facilitators to adherence identified fear of 
disclosure, concomitant substance abuse, forgetfulness, suspicions 
of treatment, complex regimens, high pill burden, decreased quality 
of life, work and family responsibilities, falling asleep and access to 
medications as the main adherence barriers [98]. Retention in HIV 
care takes two forms: pre-ART retention refers to retention in care of 
individuals not yet eligible for ART while retention on ART refers to 
individuals who remain in care after initiating ART. A review of four 
studies in South Africa and one in Malawi estimated that the median 
proportion of patients retained in pre-ART care was 45% when CD4 
eligibility threshold was 200 cells/mm3 [90]. A review of 14 studies 
reporting proportions of patients retained in care from ART eligibility 
to ART initiation estimates a median of 68% (range 14-84%) [99]. 
For retention in care after initiating ART, a systematic review of 33 
studies reporting on 39 patient cohorts estimated that 65% of patients 
are retained in ART care (range 58%-72%) after 36 months [100]. 
Factors that impact retention in care include challenges that relate to 
housing, transportation to clinics, mental health and drug abuse which 
would need to be addressed in affected individuals. Provider-patient 
relationship and clinic opening hours are other issues that need to be 
addressed to improve retention in care [91].
Virological failure and drug resistance
Initiation of treatment early in the course of infection before 
symptoms develop results in large proportions of HIV-infected 
individuals on ART; if adherence is indeed sub-optimal, this could lead 
to significant rates of virological failure and the likely development of 
drug resistance. Studies in sub-Saharan Africa of people who started 
treatment on the basis of conservative guidelines showed that 15-25% 
of patients had HIV-RNA >400 copies/mL 6-36 months after starting 
ART [101], consistent with findings from the Hlabisa HIV Treatment 
and Care programme with an estimated 15% of patients having HIV 
RNA >400 copies/mL 12 months after starting ART [102]. A further 
study from this latter cohort showed that 86% of individuals failing 
first-line ART with detectable VL had at least one drug-resistant 
mutation [103] with high levels of NNRTI- (83%) and NRTI-(81%) 
associated mutations; the median time spent on a failing regimen was 
27 months (IQR 17-41). The long duration spent on failing ART with 
accumulation of resistant mutations could be a possible explanation for 
the 15% of patients with virological failurewhose second-line regimen 
was compromised.
With increasing exposure of larger numbers of people to longer 
durations of ART, those developing ART resistance could potentially 
transmit resistant virus to their sexual partners, which would result in 
increasing numbers of new infections due to resistant virus [104,105]. 
A recent evaluation of transmitted resistance in 11 regions in six sub-
Saharan African countries including South Africa estimated prevalence 
of transmitted drug resistance in South Africa of 1.1%, but 12.3% 
in Kampala, Uganda [106]. Increasing prevalence of transmitted 
resistance would necessitate more complex and more expensive first-
line regimen which could impact on adherence and result in lack of 
virological suppression and increased transmissions making HIV 
elimination difficult.
Risk compensation
HIV has become a chronic condition, and some individuals may 
be less concerned about HIV than thirty years ago [107], which, 
coupled with the knowledge that ART may prevent HIV transmission, 
could lead to increased high risk sexual behaviour, known as risk 
compensation. However, studies in resource-limited settings with high 
HIV prevalence have not shown an increase in risky sexual behaviour 
amongst individuals initiating ART. In a Ugandan study , an increase 
in sexual activity following ART was accompanied by a 70% reduction 
in the number of unprotected sexual acts with a partner known to be 
HIV negative or of unknown serostatus [108]. In a longitudinal study in 
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South Africa on HIV-infected individuals with pre-ART and post-ART 
follow-up over seven years, high risk sexual behaviour following ART 
initiation was reduced [109]. A recent ecological study from a rural 
South African surveillance site found no evidence of an increase in high 
risk sexual behaviour at the population level following the expansion of 
ART availability, instead there was an increase in reported condom use 
at last sex with regular partners [110].
However, many studies in MSM in the developed world have shown 
an increase in high risk sexual behaviour following the introduction of 
ART coinciding with an increase in HIV incidence [111,112]. Whilst 
the frequency of HIV testing increased during this period, this was not 
sufficient to account for the observed increase in the number of new 
diagnoses [112].
As ART roll-out in sub-Saharan Africa is relatively recent, it is 
important to maintain on-going surveillance in risk behaviour in this 
region as this may change as more people become aware of the benefit 
of ART to prevent transmission.
Conclusion
Remarkable strides have been made in the past decade in potentially 
curbing the HIV epidemic, although numbers of new infections remain 
unacceptably high. No HIV prevention approach is 100% efficacious; 
all require behaviour change as individuals need to have the agency 
to decide which of the prevention methods best meet their needs at 
any particular point in time. The optimal way to tackle the epidemic 
is likely to be through combination HIV prevention [113,114], which 
combines behavioural change, treatment of STIs, ART for HIV 
positives and for pre-exposure prophylaxis for HIV negatives, male 
medical circumcision and structural approaches (Figure 1). It is now 
recognised that even within generalised epidemics, there are many 
microepidemics, hence interventions need to be focussed in nature by 
targeting areas of high transmission geographies and people at most 
risk of infections including key populations [115]
Which and how these interventions are combined may vary by 
setting using the “know your epidemic, know your response” concept 
[116]. A modelling study calibrated using the Kenyan HIV epidemic 
showed that combination of interventions which are deployed in a 
focused manner as opposed to a uniform manner with a fixed budget 
applied to both scenarios resulted in more substantial decrease in the 
incidence of HIV infections [117]. This focused intervention approach 
requires that the HIV epidemic in a particular setting is characterised 
to subnational level.The partner demonstration project, which included 
high risk serodiscordant couples in Kenya and Uganda combined ART 
given to the HIV positive partner with PrEP given to the HIV negative 
partner resulted in a 96% reduction in HIV transmission from the HIV 
positive to the HIV-negative partner.
Research is needed into how the cascade of care can be strengthened 
from the point of HIV testing to linkage of individuals to care and 
virological suppression. This would be necessary steps to maximise the 
impact the new WHO guidelines which recommend ART regardless of 
CD4 count [5].
Factors which act as barriers and facilitators for each step of the 
cascade need to be understood both at the individual and health care 
system level so that appropriate interventions can be put in place. 
Novel drug formulations that require infrequent administration 
would be a welcome addition to the HIV prevention armamentarium, 
as this strategy has the potential to increase adherence [118].
Although the HIV vaccine field has been disappointing with no 
sufficiently efficacious vaccine currently available, lessons have been 
learnt from the research with improved insight as to how HIV evades the 
immune system. This is not the time to relax, rather to intensify efforts 
in this area because an efficacious preventive vaccine would be required 
in addition to other biomedical intervention in order to make HIV 
elimination an attainable goal. The vaccine efficacy required to achieve 
this would need to be modelled in combination with other prevention 
approaches [119]. Substantial investments with smart health-financing, 
integrating of health services and political commitment would be 
required to achieve the goal of HIV elimination [119].
HIV-Uninfected  
HIV testing 
(community/facility based) 
  
HIV negative HIV-Positive  
Treatment of STIs 
Circumcision 
PrEP 
PEP 
Treatment of STIs 
ART (community & 
facility-based) 
Behaviour  
Political commitment 
Integration 
Resources/smart financing 
Equity 
Implementation research 
Elimination 
Reduced HIV 
infectiousness  Reduced HIV acquisition  
 Vaccines? 
Figure 1: Combination interventions required to eliminate HIV.
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